208 related articles for article (PubMed ID: 12926135)
1. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
3. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
Fabi A; Papaldo P; Pino MS; Ferretti G; Carlini P; Pacetti U; Di Cosimo S; Nardoni C; Giannarelli D; Sacchi I; Cognetti F
Anticancer Res; 2004; 24(3b):1963-7. PubMed ID: 15274385
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Ries F; Duhem C; Kleiber K; Dicato M
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
10. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Pagani O
Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Morales S; Lorenzo A; Ramos M; Ballesteros P; Méndez M; Almanza C; Castellanos J; Moreno-Nogueira JA; Casal J; Lizón J; Oltra A; Frau A; Machengs I; Galán A; Belón J; Llorca C
Cancer Chemother Pharmacol; 2004 Jan; 53(1):75-81. PubMed ID: 14557896
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
13. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
[TBL] [Abstract][Full Text] [Related]
14. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
19. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
